

| Study | n total | n Surgery only | HPV/P16+ rate | Primary emergence (%) | | Sites of emergence | Regional recurrence (%) | | Distant metastasis (%) | |
|-------------------|---------|----------------|-----------------------------|-----------------------|--------------|--|-------------------------|--------------|------------------------|--------------|
| | | | | ND only | Entire study | | ND only | Entire study | ND only | Entire study |
| Cummings 2021 | 540 | 63 | 82.4% | - | - | - | - | - | - | - |
| Wichmann 2021 | 115 | 19 | 43.5% P16+ 45.5% HR HPV+ | - | 7.0% | - | - | 8.7% | - | 9.6% |
| Dorobisz 2019 | 233 | 18 | Not stated | - | - | - | - | - | - | - |
| Zhou 2018 | 75 | 6 | 76.3% | 16.7% | 5.3% | 4 total (1 in surgery only group but site not stated): Oral cavity - 2 Oropharynx - 1 Supraglottis - 1 | 50.0% | - | 0.0% | - |
| Hung 2018 | 69 | 5 | Not stated | - | 11.6% | - | 40.0% | 42.0% | - | 27.5% |
| Mizuta 2018 | 80 | 27 | Not stated | 22.2% | 11.0% | Surgery only (6): Oropharynx - 2 Hypopharynx - 3 Oral cavity - 1 Multi-modality treatment (3): Nasopharynx - 1 Oropharynx - 1 Hypopharynx - 1 | - | 20.0% | - | 12.5% |
| Axelsson 2017 | 68 | 7 | 69.5% | - | 1.5% | Oropharynx - 1 (initial treatment not specified) | - | 8.8% | - | 1.5% |
| Dou 2016 | 77 | 30 | Not stated | 33.3% | 18.1% | 14 total (10 in surgery group but site not stated): Nasopharynx - 3 Oropharynx - 3 Oral cavity - 3 Hypopharynx - 3 Sinonasal - 1 Oesophagus - 1 | 33.3% | 20.8% | 3.3% | 7.8% |
| Lou 2015 | 133 | 46 | Not stated | 37.0% | 21.8% | Surgery only (17): Nasopharynx - 6 Oropharynx - 3 Hypopharynx - 5 Larynx - 3 Multi-modality (12): Nasopharynx - 4 Oropharynx - 3 Hypopharynx - 1 Oesophagus - 2 Lung - 2 | - | 13.5% | - | 3.8% |
| Wongsritrang 2012 | 139 | 17 | Not stated | - | 8.6% | 12 total (initial treatment not specified): Nasopharynx - 2 Sinonasal - 2 Oropharynx - 3 Oral Cavity - 2 Larynx - 1 Oesophagus - 2 | - | 13.7% | - | 7.9% |
| Rodel 2009 | 58 | 8 | Not stated | - | 7.0% | 4 total (initial treatment not specified): Larynx - 1 Hypopharynx - 2 Lung - 1 | - | 22.4% | - | 36.2% |
| Miller 2008 | 17 | 9 | Not stated | 11.1% | 5.9% | Surgery only (1): Oropharynx - 1 | 22.2% | 17.6% | 0.0% | 5.9% |
| Patel 2007 | 70 | 10 | Not stated | 20.0% | 11.4% | 8 total (2 in surgery group but site not specified): Oropharynx - 4 Oral Cavity - 2 Larynx - 2 | 0.0% | 20.0% | - | 7.1% |
| Iganej 2002 | 106 | 29 | Not stated | 27.6% | 17.9% | 19 total (initial treatment not specified): Nasopharynx - 2 Oropharynx - 10 Supraglottis - 3 Hypopharynx - 4 | - | 34.0% | - | 9.4% |

Table 3: Primary emergence and recurrence data.